| scholarly article | Q13442814 |
| P50 | author | Eduardo Bruera | Q60386359 |
| P2093 | author name string | Shalini Dalal | |
| David Hui | |||
| Egidio Del Fabbro | |||
| Rony Dev | |||
| Marvin O Delgado-Guay | |||
| Nikhil Sobti | |||
| P2860 | cites work | Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study | Q26828911 |
| The Edmonton Symptom Assessment System (ESAS): A Simple Method for the Assessment of Palliative Care Patients | Q28277097 | ||
| Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging | Q31831299 | ||
| Androgen replacement therapy in the aging male--a critical evaluation | Q34277156 | ||
| Prevalence of hypogonadism in males aged at least 45 years: the HIM study | Q35037892 | ||
| Preliminary report: vitamin D deficiency in advanced cancer patients with symptoms of fatigue or anorexia | Q35599827 | ||
| Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report | Q39874674 | ||
| The determination of bio-available testosterone | Q40374733 | ||
| The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors | Q43563153 | ||
| Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes | Q44446866 | ||
| Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry | Q44757074 | ||
| Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids | Q44760826 | ||
| American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update. | Q44983422 | ||
| Low serum testosterone and estradiol predict mortality in elderly men. | Q46033005 | ||
| Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial | Q48477274 | ||
| Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia | Q48713782 | ||
| The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. | Q50918956 | ||
| Hypogonadism in male patients with cancer. | Q51498250 | ||
| The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. | Q53820607 | ||
| Hypogonadism in male patients with metastatic cancer prior to chemotherapy | Q70333069 | ||
| The Apparent Free Testosterone Concentration, An Index of Androgenicity | Q70616223 | ||
| Total and free testosterone during pregnancy | Q70648514 | ||
| Loss of circadian rhythmicity in blood testosterone levels with aging in normal men | Q71709444 | ||
| Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer | Q80658401 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypogonadism | Q938107 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 1586-1593 | |
| P577 | publication date | 2014-02-27 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer | |
| P478 | volume | 120 |
| Q57797112 | Q57797112 |
| Q57797128 | Q57797128 |
| Q40121315 | A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer |
| Q26768142 | Acupuncture and Related Therapies for Symptom Management in Palliative Cancer Care: Systematic Review and Meta-Analysis |
| Q55357541 | Androgen-Induced Immunosuppression. |
| Q40112597 | Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer |
| Q90234933 | Blood concentrations of vitamins B1, B6, B12, C and D and folate in palliative care patients: Results of a cross-sectional study |
| Q33840617 | Clinical significance of androgen secretion disorders in men with a malignancy. |
| Q91604235 | IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm |
| Q35981188 | Identifying nutritional, functional, and quality of life correlates with male hypogonadism in advanced cancer patients |
| Q62141789 | Loss of muscle mass in the end of life in patients with advanced cancer |
| Q57169920 | Lower Circulating Androgens Are Associated with Overall Cancer Risk and Prostate Cancer Risk in Men Aged 25-84 Years from the Busselton Health Study |
| Q33420679 | Medical Manuscript: Serum Total Testosterone as a Prognostic Indicator in Male Patients With Terminal Cancer |
| Q36626638 | Prognostication of Survival in Patients With Advanced Cancer: Predicting the Unpredictable? |
| Q39175916 | Range of Effective Corticosteroid Doses for Alleviating Dyspnea in Terminal Cancer Patients: A Retrospective Review |
| Q64929589 | Scalp hair cortisol and testosterone levels in patients with sarcoidosis. |
| Q36391526 | Sex differences and sex hormones in anxiety-like behavior of aging rats |
| Q37373061 | Symptom clusters and survival in Portuguese patients with advanced cancer |
| Q35068943 | The implications of low testosterone on mortality in men |
Search more.